labour2 but is unlikely to cause a rapid increase in the third stage because the increase was delayed in some patients until after the umbilical cord had been clamped and cut. If the increase in oxytocin is maternal in origin it may be due to increased release from the posterior pituitary or a sudden reduction in metabolism. Suddenly reduced metabolism is perhaps unlikely because the placenta (the main source of oxytocinase) was removed after the increase in oxytocin concentration. The posterior pituitary is thus the likely source of the endogenous oxytocin; it is tempting to suggest that vaginal distension during delivery could cause the release of oxytocin as a result of the Ferguson reflex."
In conclusion, in 40% of the women who did not receive oxytocin treatment plasma concentrations of endogenous oxytocin increased. The increase was similar to that that always occurs after intramuscular administration of synthetic oxytocin. As yet we cannot predict in which women the increase will occur; therefore, assuming that the increase is important in the natural third stage of delivery we advise that oxytocin should be given routinely.
We thank the consultants of the Princess Mary Maternity Hospital for allowing us to study their patients, the women themselves, and the department of medical statistics, University of Newcastle upon Tyne. We are grateful for financial support from the research committee, Newcastle Health Authority (reference 86/56).
Introduction
Adding vasodilators to diuretics is now standard practice in the management of patients with severe heart failure in whom no surgically remediable cause is present. Not all vasodilators are effective, however, and the reason is not clear.
In acute heart failure vasodilators may increase cardiac output and reduce high pulmonary capillary wedge pressures, but in chronic heart failure these changes do not correlate with patients' symptoms. In chronic heart failure exercise tolerance is related to limb and therefore skeletal muscle blood flow and vasodilators may be more important in improving skeletal muscle blood flow than in changing central haemodynamics. 2 In chronic heart failure the renin-angiotensin and sympathetic nervous systems are often activated and both may further be activated by diuretics; this may limit the efficacy of these agents. 3 The angiotensin converting enzyme inhibitors partially reverse these neurohumoral changes, which may explain their long term symptomatic benefit.45 Conversely, other vasodilators that stimulate the renin-angiotensin and sympathetic nervous systems may not produce long term benefit.6
Though angiotensin converting enzyme inhibitors are used routinely for treating severe heart failure, they are not ideal; some patients fail to respond and others develop undesirable side effects. New vasodilators are clearly needed but there is no simple way of evaluating them. Apart from vasodilator activity they must be shown to improve symptoms when given long term and they should also be shown not to potentiate the neurohumoral responses to heart failure.
We describe two studies evaluating the acute haemodynamic and longer term symptomatic effects of flosequinan, a new, direct acting venous and arteriolar vasodilator,7 in patients with heart failure.
Patients and methods

ACUTE HAEMODYNAMIC EFFECTS
Ten patients with chronic heart failure due to ischaemic heart disease entered the study. Two were withdrawn; one developed ventricular tachycardia 10 hours after taking the drug and in the other patient the drug could not be detected in plasma samples. The eight who completed the study were aged 46-70, and two were women. All the patients were taking 160-200 mg frusemide daily. The patients were admitted to hospital because of uncontrolled heart failure and were considered to need vasodilators. They were in hospital for at least 24 hours before the study. On the study day a thermodilution catheter was inserted into the pulmonary artery at least two hours before the baseline measurements. Minute ventilation, oxygen consumption, and carbon dioxide production were measured at minute intervals during the exercise test with an on line gas analyser (P K Morgan). Blood was sampled from an antecubital vein with the patients supine, erect, and at symptom limited maximum for plasma renin activity and noradrenaline concentrations.
Limb bloodflow
The effect of flosequinan on limb blood flow was measured before and after a second exercise test. Sixty minutes after the symptom limited exercise test, by which time limb blood flow had returned to preexercise levels, the patients performed a submaximal test. They were asked to exercise to a workload which required an oxygen consumption of 12 ml/kg/min. If they failed to reach this workload the submaximal test was terminated at the last completed stage before the one in which the patient became limited by symptoms. The workload of this test was kept constant for each patient throughout. Forearm and calf blood flow were measured by venous occlusion plethysmography with mercury in Silastic strain gauges at rest before the test and at minute intervals from three to 13 minutes after the end of the test.2
Plasma renin activity and catecholamines Plasma renin activity was measured by radioimmunoassay (Rianen angiotensin I (iodine-125) radioimmunoassay kit) and plasma catecholamine concentrations by high performance liquid chromatography.9
Study design and drug administration
The study had a randomised, double blind crossover design which after a dose titration phase compared placebo with active treatment. Each patient was treated with placebo at the start of the study until two consecutive symptom limited exercise times did not increase by more than 5%. Over the next five weeks the patients were given single blind weekly incremental doses of flosequinan of 30 mg, 50 mg, 75 mg, 100 mg, and 125 mg once daily. The optimum dose of flosequinan was chosen and the patients received this or placebo in a double blind manner for the next four weeks, according to a randomisation schedule, and were then crossed over to the other treatment for a further four weeks. If they deteriorated before the end of the first four weeks they were immediately given the other treatment, and if they deteriorated before the end of the second four weeks the study was terminated. 
ETHICS
The studies were approved by the local ethical committee. They were conducted under the clinical BMJ VOLUME 297trial exemption scheme of the Department of Health and Social Security, and flosequinan had not been evaluated by the Committee on the Safety ofMedicines.
Results
ACUTE HAEMODYNAMIC EFFECTS
The mean (SEM) pretreatment cardiac index was 1 8 (0 1) 1/min/m2. It increased significantly at three hours to a mean of 2 1 (0 1)1/min/m2 (p<005) and at 24 hours to 2 2 (0 2)1/min/m2 (p=0 04). Table I shows the mean increase in cardiac index over the 24 hour study period and table lI the individual maximum values of cardiac index obtained and the times at which they occurred. All the patients showed an increase in cardiac index.
The mean (SEM) pulmonary capillary wedge pressure before flosequinan was 30 9 (3 2) mm Hg. It fell to a nadir of 19 4 (2 1) mm Hg after two hours and was 20 3 (2 4) mm Hg at 24 hours (p<001). Table III shows the mean decrease in pulmonary capillary wedge pressure over the study period. Table II shows the individual minimum values of pulmonary capillary wedge pressure recorded and the times at which these occurred. All patients showed a decrease in pulmonary capillary wedge pressure. There were no significant changes in systemic arterial pressure or heart rate during the study.
LONGER TERM SYMPTOMATIC EFFECTS Exercise tolerance
During the single blind dose ranging phase of the study all 11 patients were found to improve most with 125 mg daily, and this dose was therefore chosen for all patients during the double blind phase. Figure 1 shows the changes in symptom limited exercise time on the treadmill during the double blind crossover phase of the study and also the exercise time at the end of the placebo run in period. There was no difference between the mean (SEM) exercise time at the end of the placebo run in period (9 2 (1 6) minutes) and that at the end of the double blind placebo period (9-9 (1 6) minutes), indicating that the patients were stable. There was a significant increase from the double blind placebo exercise time of (1-6) minutes to 12 7 (1 3) minutes after four weeks of active treatment (treatment effect: F =318, df=1,5-9 (assuming unequal variances); p=O OOl). There was no evidence of tachyphylaxis to the drug over the treatment period. In addition to increasing exercise tolerance, flosequinan reduced the patients' perceived exertion during submaximal exercise (table IV) . Mean Borg score fell from 10 6 (SEM 0 8) during the double blind placebo period to 9 5 (0 7) after four weeks of active treatment in the 11 patients who completed stage 1 of the treadmill exercise protocol (treatment effect: F=2 22, df=1,9; p=0 17). In the nine patients who completed stage 2 it fell from a placebo value of 12 4 (1 -2) to 11 2 (1 1) after four weeks of active treatment (treatment effect: F=5-85, df=1,4-6 (assuming unequal variances); p=0O06). Effects on limb bloodflow Figure 2 shows the changes in calf blood flow before and after exercise during the double blind part of the study. Normal resting calf blood flow is approximately 3-0 ml/dl/min, and in response to the same workload a BMJ VOLUME 297
16 JULY 1988 z = LI normal person would increase calf blood flow to greater than 5 0 ml/dl/min three minutes after the end of exercise.2 Thus the patients had a reduced blood flow at rest and the response to exercise was also attenuated. Flosequinan increased calf blood flow at rest and after exercise (treatment effect: F=7448, df=1,9; p<O-OO1).
The normal response to upright exercise is to redirect blood from the non-exercising forearm to the exercising calf and thereby cause a fall in forearm blood flow. With placebo forearm blood flow fell from a mean of 1 9 (SEM 0 2) ml/dl/min at rest to 1-6 (03) ml/dl/min three minutes after exercise and remained at this level up to 13 minutes after exercise. Flosequinan increased resting forearm blood flow to 2-6 (02) ml/dl/min, and three minutes after exercise the value was 2-2 (0 3) ml/dl/min; and it also remained at this level up to 13 minutes after exercise (treatment effect: F=6 25, df= 1,9; p=003) (table IV).
Plasma renin activity and catecholamines Table IV also gives the supine plasma renin activity and plasma noradrenaline concentrations at rest and during exercise during the double blind part of the study. There were no significant differences between any of the measurements, but the mean supine plasma renin activity tended to fall with active treatment and mean plasma noradrenaline concentrations were lower both supine and erect with active treatment. Plasma noradrenaline concentrations at symptom limited maximum exercise were similar despite the mean exercise tolerance of the patients being considerably greater with flosequinan. The period and carryover effects were not statistically significant in any of the analyses.
No patient developed any drug related biochemical or haematological abnormality. In the exercise study two patients complained of transient headache and two had a taste disturbance, probably due to the excretion of the drug in saliva.
Discussion
The first of these studies shows that flosequinan had favourable central haemodynamic effects in patients with severe heart failure. These effects lasted up to 24 hours after a single oral dose. This is because the drug has an active metabolite with a half life exceeding 30 hours'0 and is therefore suitable for once daily use. In the second study the drug also improved the symptom limited exercise tolerance of patients with severe heart failure. It having a unique role in the management of patients with heart failure, particularly as they are not always well tolerated. Flosequinan undoubtedly has the properties theoretically desirable in a vasodilator to be used to treat patients with heart failure, and the improvement in symptoms that we have recorded suggests that it is likely to be a useful alternative to angiotensin converting enzyme inhibitors.
Introduction
Familial hypercholesterolaemia is due to a single gene defect affecting the activity of receptors for low density lipoprotein. This leads to a reduction in the number of high affinity receptors for low density lipoprotein on peripheral and hepatic cells and a consequent increase in the plasma low density lipoprotein cholesterol concentration due to reduced plasma clearance. Familial hypercholesterolaemia is one of the commonest single gene disorders, having an incidence of one in 500 and affecting an estimated 100 000 people in the United Kingdom. These patients have a greatly increased risk of coronary heart disease; the heterozygotes are estimated to have a 50% chance of dying from myocardial infarction before the age of 60,' and homozygotes rarely survive to the third decade. It is thus a condition in which there is a clear indication for dietary and pharmacological intervention aimed at reducing the high concentrations of low density lipoprotein. The response to diet is usually poor and treatment with a single agent is often inadequate. Combination treatment, particularly with bile acid sequestrant resins and nicotinic acid, has reduced concentrations of low density lipoprotein. 2 The side effects of nicotinic acid, however, make this approach unsuitable for most patients.
We used an anion exchange resin (cholestyramine), the treatment of choice in familial hypercholesterolaemia, alone and in combination with bezafibrate, one of the newer fibrate drugs, in 18 patients with familial hypercholesterolaemia. The study compared the relative efficacy of cholestyramine and bezafibrate in lowering low density lipoprotein cholesterol concentration in patients with this condition and determined whether combination treatment could reduce low density lipoprotein to acceptable concentrations.
Patients and methods
Eighteen patients with heterozygous familial hypercholesterolaemia were recruited from the outpatient clinic. All had a total cholesterol concentration >7 5 mmol/l or a low density lipoprotein cholesterol concentration >4 9 mmol/l (concentration before treatment or highest concentration while patient was receiving treatment), and they or a first or second degree relative had tendon xanthomas. The 10 women and eight men had a mean age of 41 (range 26 to 52) years.
All patients were maintained on a formal diet low in fat (30% of total calories: 10% each of saturated, monounsaturated, and polyunsaturated fatty acids) and low in cholesterol (less than 300 mg/day); they were provided with regular dietary counselling throughout the study. Patients with diabetes or with liver, kidney, thyroid, or parathyroid diseases were excluded, as were pregnant or lactating women. None of the patients was taking drugs known to affect lipid metabolism.
